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Toxoplasma gondiiToxoplasma gondii is an important food and waterborne pathogen that causes severe disease in immuno-
compromised patients. Bumped kinase inhibitors (BKIs) have an antiparasitic effect on T. gondii tachyzo-
ite growth by targeting T. gondii calmodulin-domain protein kinase 1 (TgCDPK1). To identify mutations
that confer resistance to BKIs, chemical mutagenesis was performed, followed by selection in media con-
taining either 250 or 1000 nM 1NM-PP1. Whole-genome sequence analysis of resistant clones revealed
single nucleotide mutations in T. gondii mitogen-activated protein kinase 1 (TgMAPK1) at amino acids
162 (L162Q) and 171 (I171N). Plasmid constructs having the TgMAPK1 L162Q mutant sequence success-
fully replaced native TgMAPK1 genome locus in the presence of 1000 nM 1NM-PP1. The inhibitory effect
of 1NM-PP1 on cell division observed in the parent clone was decreased in 1NM-PP1-resistant clones;
however, effects on parasite invasion and calcium-induced egress were similar in both parent and resis-
tant clones. A plasmid construct expressing the full length TgMAPK1 splicing isoform with L162Q muta-
tion successfully complemented TgMAPK1 function in the pressure of 250 nM 1NM-PP1 in plaque assay.
1NM-PP1-resistant clones showed resistance to other BKIs (3MB-PP1 and 3BrB-PP1) with different levels.
Here we identify TgMAPK1 as a novel target for 1NM-PP1 activity. This inhibitory effect is mediated
through inhibition of tachyzoite cell division, and can be overcome through mutations at multiple resi-
dues in TgMAPK1.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.1. Introduction
Toxoplasma gondii is an obligate intracellular parasite of the phy-
lum Apicomplexa, which includes the causative pathogens of toxo-
plasmosis, malaria, and cryptosporidiosis. Bumped kinase
inhibitors (BKIs) have been shown to inhibit tachyzoite growth in
T. gondii (Lourido et al., 2010; Ojo et al., 2010; Sugi et al., 2010; Lar-
son et al., 2012), Cryptosporidium parvum infection (Murphy et al.,
2010) and transmission of the malaria parasite from humans to
mosquitoes (Ojo et al., 2012). BKIs are protein kinase inhibitor ana-
logs which primarily affect analog-sensitive protein kinases con-
taining a small amino acid at the gatekeeper position (Shokat andVelleca, 2002). Gatekeeper amino acids are found at the entrance
of the protein kinase ATP-binding pocket; the size and shape of this
amino acid greatly affects the susceptibility of protein kinases to ki-
nase inhibitor analogs (Shokat and Velleca, 2002). Analog-sensitive
protein kinases are rarely encoded in mammalian genomes.
The genomes of Toxoplasma, Neospora, and Cryptosporidium en-
code for calmodulin-domain protein kinase 1 (CDPK1) homologs
(TGME49_101440, NCLIV_011980, and cgd3_920 in the EuPathDB
http://eupathdb.org/eupathdb/) containing a glycine at the gate-
keeper amino acid position. Both TgCDPK1 (Lourido et al., 2010;
Murphy et al., 2010; Sugi et al., 2010; Larson et al., 2012) and
CpCDPK1 (Murphy et al., 2010) have been conﬁrmed as the pri-
mary targets of BKIs, however the T. gondii genome encodes for
other analog-sensitive protein kinases containing a small amino
acid such as Ala, Ser and Thr at the gatekeeper position, suggesting
the possibility of multiple targets (Sugi et al., 2010). BKIs therefore
represent a promising new class of antiparasitic compounds.
To predict the frequency at which BKI-resistant parasites may
arise, identiﬁcation of mutations conferring resistance to these
inhibitors is required. Resistance to BKIs is predicted to occur
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tein kinases, as well as other amino acids affecting the afﬁnity of
protein kinase inhibitors to their respective targets. Mutation of
the gatekeeper residue of TgCDPK1 from wild-type (WT) glycine
to methionine, which contains a larger side chain than that of gly-
cine, has been shown to confer resistance in transfected parasites
(Lourido et al., 2010; Murphy et al., 2010; Sugi et al., 2010; Larson
et al., 2012). This effect is not limited to gatekeeper residues
though, as mutation at other sites within the protein kinase do-
main have been shown to confer resistance to ATP pocket binding
inhibitors such as imatinib (Weisberg and Grifﬁn, 2000) and niloti-
nib (Ray et al., 2007). Accordingly, we chose to screen for all muta-
tions conferring resistance to BKIs, including those not found at the
gatekeeper residue, using randomly mutated parasites. This strat-
egy of using chemically mutated parasite lines, followed by
whole-genome sequencing, has recently been validated in T. gondii
as a means of identifying relevant mutations (Farrell et al., 2012).
In the present study, we used the protein kinase inhibitor ana-
log 1NM-PP1 to select for chemically mutated resistant parasite
clones in T. gondii type II strain PLK/DUAL (Unno et al., 2009). To
fully characterize the inhibitory effects of BKIs, replication inhibi-
tion during bradyzoite differentiation, along with effects of inhibi-
tors on parasite stress responses, should be considered. To observe
such inhibitory effects across different stages of the parasite life cy-
cle, we employed a PLK/DUAL strain. This strain was derived from a
type II PLK strain, and has the capacity for both tachyzoite and bra-
dyzoite differentiation (Unno et al., 2009). Whole-genome
sequencing was used to identify mutations in protein kinases
which conferred resistance to BKIs. We then analyzed the effect
of these mutations on cell invasion, host cell egress, and cell divi-
sion to better understand the mechanism of resistance.
2. Materials and methods
2.1. Tested reagents
1NM-PP1 was purchased from Merck KGaA (Darmstadt, Ger-
many). 3BrB-PP1 and 3MB-PP1 were purchased from Toronto Re-
search Chemicals (Ontario, Canada).
2.2. Parasite cultures
Tachyzoites of the T. gondii PLK/DUAL (Unno et al., 2009) strain
(kindly provided by Dr. Y. Takashima, Gifu University, Gifu, Japan)
and PLK/hxgprt strain (Roos et al., 1994) (NIH AIDS Reagent Pro-
gram, Division of AIDS, NIAID, NIH #2860) were used in this study.
Parasites were maintained in monolayers of Vero cells cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Nissui, Tokyo, Ja-
pan) containing 1% fetal calf serum (FCS) and 2 mM L-glutamine,
streptomycin, and penicillin. Host Vero cells were passaged in
the same medium containing 5% FCS. For assays, tested reagents
or a DMSO control solvent were added to the same medium with
1% FCS (infection medium).
2.3. Chemical mutagenesis
Random mutagenesis was introduced using N-ethyl-N-nitro-
sourea (ENU) (Sigma-Aldrich, St. Louis, MO, USA) as previously de-
scribed (Nagamune et al., 2007). PLK/DUAL tachyzoites (5.0  107)
were inoculated onto Vero cells cultured in T75 ﬂasks. At 2 h post
inoculation (hpi), parasites were exposed to ENU (500 lg/mL) for
1 h in serum-free culture medium, then washed three times in
infection medium. They were then incubated at 37 C for an addi-
tional 24 h, followed by 1NM-PP1 selection. Mutated parasites
were selected using 1NM-PP1 at either 250 or 1000 nM for 3 weeks
with medium changes every 2 days. Parasites were passaged to anew host monolayer every 7 days with host cells ruptured by pas-
sage through a 25-G needle to remove uninfected cells. Resistant
parasites were cloned by limiting dilution and designated as either
PLK/DUAL res.1 for 250 nM selection or PLK/DUAL res.2 for
1000 nM selection.
2.4. Sequence analysis and structure prediction of mutated TgMAPK1
The peptide sequence of the TgMAPK1 (GenBank: AY684849)
protein kinase domain (from amino acid 81 to 532) was aligned
with HsErk5 (GenBank: NP_002740.2), and CpCDPK1 (GenBank:
3NCG_A). Subdomain prediction was performed according to the
method of Hanks and Hunter (1995). ATP-binding sites were pre-
dicted by NCBI conserved domain search (Marchler-Bauer et al.,
2011). 1NM-PP1-binding sites were predicted from the structure
of 1NM-PP1 bound CpCDPK1 (Murphy et al., 2010) (PDB: 3NCG).
For homology modeling, the TgMAPK1 protein kinase domain
(amino acid residues 81–532) was used for structure calculation
by SWISS-MODEL automated mode (Arnold et al., 2006) using
the crystal structure of Homo sapiens MAPK7 (HsErk5) bound with
inhibitor (PDB: 4B99) as a template. The predicted structure was
superimposed over the 1NM-PP1-bound CpCDPK1 structure
(PDB: 3NCG) using UCSF Chimera (Pettersen et al., 2004).
2.5. Assay for BKIs inhibition of parasite growth
The growth of PLK/DUAL and resistant clones was evaluated
using the DsRed-Express reporter gene expressed under the con-
trol of a SAG1 promoter. Parasites were pre-incubated with various
concentrations of 1NM-PP1, 3BrB-PP1, and 3MB-PP1 or the control
solvent (DMSO) for 10 min at room temperature. 5000 parasites
per well were inoculated on full Vero cell monolayers in 48-well
plates, and cultured with the tested reagent for 6 days. After incu-
bation, media were aspirated and cells lysed using phosphate buf-
fered saline (PBS) containing 0.5% sodium dodecyl sulfate to reduce
background ﬂuorescence. Cell lysates were moved to 96 well plates
and measured using an SH-9000 ﬂuorimeter (Corona Electronic,
Ibaraki, Japan) with an excitation wave length of 540 nm and an
emission wave length of 590 nm. Background ﬂuorescence intensi-
ties were detected using mock infected wells, and subtracted from
the values of all wells.
2.6. Whole-genome sequencing and single nucleotide variants (SNV)
identiﬁcation
SOLiD sequencing libraries were generated from genomic DNA
of PLK/DUAL, PLK/DUAL res.1, and PLK/DUAL res.2 strains. Libraries
were sequenced using a 5500xl SOLiD system (Life Technologies,
Carlsbad, CA) according to the manufacturer’s instructions using
75-bp single-end reads. Sequencing data has been submitted to
DDBJ (DDBJ: DRA000618). Reads were mapped to the T. gondii
ME49 genome (ToxoDB http://toxodb.org/version 2008_07_23)
using alignment software BWA (Li et al., 2009). SNVs were called
with SAMTOOLS (Li et al., 2009) and ﬁltered using a minimal cov-
erage of 10, a maximum coverage of 100, and an alternative bases
positive rate of >80%. The average depth was calculated with a 100-
kbp window. SNVs were further ﬁltered using a predicted gene
model in ToxoDB version 7.2.
2.7. Transgenic parasites
Approximately 2-kbp sequences of TgMAPK1 adjacent to the mu-
tated sites, and lacking a promoter and start codon were ampliﬁed
from genomic DNA of parent and resistant clones. Primers
TgMAPK1_F1 and TgMAPK1cla1_R2 (Supplemental Table 1) were
used to generate the ﬁrst-half fragment, and primers TgMAPK1_R1
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the second-half fragment. The ﬁrst-half fragment was digested with
EcoRI and ClaI, while the second-half fragmentwas digestedwith ClaI
and SmaI. The two fragments were inserted into the EcoRI and SmaI
sites of pBluescript KS() to produce a ClaI site without affecting
the TgMAPK1 coding sequence. Plasmids containing sequences from
PLK/DUAL, PLK/DUALres.1, andPLK/DUALres.2weredesignatedpTg-
MAPK1_WT, pTgMAPK1_LQ, and pTgMAPK1_IN, respectively.
Twenty micrograms of each plasmid was transfected, either sepa-
rately or in combination, into 1.8  107 freshly puriﬁed PLK/DUAL
cells with Nucleofection™ and basic parasite Nucleofector

kit 1,
using Nucleofector

II device program U-33 (Lonza, Basel, Switzer-
land). Following transfection, cells were incubated at 37 C for 24 h,
and treatedwith1000 nM1NM-PP1.After 3 weeksof selection, geno-
mic DNA from parasites was puriﬁed using a QIAamp DNA mini kit
(QIAGEN) according to the manufacturer’s instructions.
PCR of the genomic locus containing TGME49_112570 was per-
formed using KOD Fx Neo (TOYOBO, Osaka, Japan) and 35-mer
primers genomic_Locus_primer_F and genomic_Locus_primer_R
(Supplemental Table 1) with step-down PCR under the following
conditions: initial denaturation at 94 C for 2 min, 5 cycles of
98 C for 10 s and 74 C for 10 min, 5 cycles of 98 C for 10 s and
72 C for 10 min, 5 cycles of 98 C for 10 s and 70 C for 10 min,
and 25 cycles of 98 C for 10 s and 68 C for 10 min, followed by
a ﬁnal extension at 68 C for 10 min. Ampliﬁed PCR products were
used for the restriction enzyme cut assay. Sequence analysis of
mutation sites was performed using primers Mutation_screen_F
and Mutation_screen_R (Supplemental Table 1). Resistant para-
sites were cloned by limiting dilution; sequence analysis was per-
formed as described above.
For the functional expression of TgMAPK1, a TgMAPK1 splicing
variant was investigated. Gene modeling in ToxoDB suggests the
presence of eight exons in TgMAPK1, and is supported by RNA-
seq data demonstrating mRNA containing eight exons. Splicing at
intron 7 was conﬁrmed by RT-PCR using primers Splicing_con-
ﬁrm_F and Splicing_conﬁrm_R (Supplemental Table 1).
Because of the long mRNA sequence, we could not amplify the
TgMAPK1 full length isoform in a single PCR reaction. Accordingly,
we divided the gene into two parts; we ampliﬁed the 1st half from
total RNA using primers 1st_half_F and 1st_half_R (Supplemental
Table 1), the 2nd half using primers 2nd_half_F and 2nd_half_R
(Supplemental Table 1). The TgMAPK1 full length isoform was then
ampliﬁed by overlapping PCR using the 1st half and 2nd half PCR
products as templates with primers 1st_half_F and 2nd_half_R. This
full-length isoform was then cut using EcoRI and EcoRV restriction
enzymes, and inserted into the EcoRI and EcoRV site of pMini.ht.3x-
FLAG (Sugi et al., 2010). The resulting plasmid expressed TgMAPK1
tagged with a C-terminal 3xFLAG driven by a GRA1 promoter. Plas-
mids containing theWT sequence and L162Qmutation were desig-
nated pTgMAPK1-FLAG and TgMAPK1L162Q-FLAG, respectively. As a
control, GFP was ampliﬁed from the pMini.GFP.ht (Arrizabalaga
et al., 2004) using primers GFP_F andGFP_R (Supplemental Table 1),
and inserted into the BglII and EcoRV site of pMini.ht.3xFLAG to ex-
press C-terminal 3xFLAG-tagged GFP. Plasmids were transfected
into T. gondii strain PLK/hxgprt, selected with 25 lg Mycophenolic
acid and 50 lg Xanthine, as described (Arrizabalaga et al., 2004),
and cloned by limiting dilution. Cloned parasites stably expressing
WT and L162Qmutated TgMAPK1 or GFP tagged with 3xFLAGwere
designated to PLK/TgMAPK1-FLAG, PLK/TgMAPK1L162Q-FLAG and
PLK/GFP-FLAG, respectively.
2.8. Invasion assay
Invasion assays were performed as described previously (Sugi
et al., 2010). Brieﬂy, freshly harvested and puriﬁed parasites were
incubated in the tested reagent for 10 min at room temperatureand inoculated onto a monolayer of Vero cells for 30 min at 37 C
with 500 nM 1NM-PP1 or with DMSO. Following invasion, cells
were washed three times with ice cold PBS, and extracellular par-
asites stained with anti-SAG1 monoclonal antibodies (1:1000 dilu-
tion) [TP3] (Santa Cruz Biotechnology, Santa Cruz, CA) in PBS
containing 2% FCS for 30 min. After staining, the cells were washed
three times with PBS containing 2% FCS, ﬁxed with 4% paraformal-
dehyde in PBS, and stained with ALEXA 633 conjugated goat anti-
mouse antibodies. Stained cells were visualized with a Zeiss
LSM510 system. Microscopic ﬁelds were chosen at random; extra-
cellular parasites were detected using anti-SAG1 antibodies and to-
tal parasites detected by DsRed-Express.
2.9. Calcium-induced egress assay
A calcium-induced egress assay was performed as described
(Lourido et al., 2010). Brieﬂy, puriﬁed parasites were inoculated
onto a monolayer of Vero cells and allowed to invade for 2 h. At
2 hpi, the cells were washed with PBS to remove non-invaded par-
asites and incubated in infection medium overnight. At 30 hpi, the
media were changed to media containing the reagent of interest
and incubated for 10 min at room temperature. Calcium was in-
duced by the addition of media containing 5 lM A23187 along
with the reagent of interest. Cells were incubated at 37 C for
5 min, and egress stopped by addition of 4% paraformaldehyde in
PBS for 10 min on ice.
2.10. Cell division assay
Cell division assays were performed as described elsewhere
(Kurokawa et al., 2011). Brieﬂy, parasites were inoculated into an
eight-well chamber slide containing Vero cells grown in a mono-
layer, and incubated at 37 C for 1 h. Following incubation, cells
were washed with warm infection medium three times to remove
non-invaded parasites, followed by incubation in infection med-
ium with 250 nM 1NM-PP1 or DMSO. After incubation for 12 and
24 h, the cells were ﬁxed with 4% paraformaldehyde in PBS for
10 min at room temperature, washed three times with PBS, dried
at room temperature, and mounted with Fluorescence Mounting
Medium (Dako, Glostrup, Denmark). Cells were observed by ﬂuo-
rescence microscopy (Olympas, Tokyo, Japan). Microscopic ﬁelds
were chosen at random to count parasitophorous vacuoles. Aver-
age numbers of tachyzoites per vacuole were calculated.3. Results
3.1. Generation of 1NM-PP1-resistant parasites by N-ethyl-N-
nitrosourea (ENU)-induced random mutagenesis
To identify mutations conferring resistance to BKI 1NM-PP1, T.
gondii strain PLK/DUAL was mutagenized by treatment with ENU,
and selected with either 250 or 1000 nM 1NM-PP1. Two indepen-
dent 1NM-PP1-resistant parasite clones were generated, desig-
nated PLK/DUAL res.1 and PLK/DUAL res.2. Sensitivity of resistant
clones to 1NM-PP1 was determined using a tachyzoite growth as-
say. IC50 values for clones PLK/DUAL res.1 and PLK/DUAL res.2 were
290 and 210 nM, respectively, compared to 84 nM for parental
strain PLK/DUAL (Fig. 1A). The effect of 1NM-PP1 treatment was re-
duced in resistant clones, especially at 250 and 500 nM (Fig. 1A).
3.2. Identiﬁcation of SNPs in the resistant clones
To identify mutations conferring resistance to 1NM-PP1, the
genomes of PLK/DUAL, PLK/DUAL res.1, and PLK/DUAL res.2 were
sequenced using a 5500xl SOLiD system. Total reads of
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Fig. 1. Establishment of 1NM-PP1 resistant clones and whole-genome sequence. (A) Tachyzoite growth inhibition by 1NM-PP1 was calculated based upon expression of a
DsRed Express ﬂuorescent reporter driven by a SAG1 promoter. Cells were cultured for 6 days; ﬂuorescent signals from cell lysates were detected using a ﬂuorimeter, and
expressed as relative ﬂuorescent units. Error bars indicate the standard deviations across three independent experiments. IC50 values for three clones are inset. (B) Summary
of sequence reads that could be aligned to the T. gondii genome. (C) Genome-wide average sequence depths of a 100-kbp window from PLK/DUAL (black), PLK/DUAL res.1
(red), and PLK/DUAL res.2 (blue) are plotted. The horizontal red line shows 10 depth. Scale bar = 10 Mbp. Putative SNVs in PLK/DUAL res.1 (red triangle) and PLK/DUAL res.2
(blue triangle), based on the coding sequence of PLK/DUAL, are plotted.
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res.1, and PLK/DUAL res.2, respectively, were mapped to the T. gon-
dii ME49 reference genome. Coverage throughout the genome was
97%, 96%, and 97%, respectively (Fig. 1B). The mapped sequence
reads showed unbiased coverage and depth throughout the gen-
ome (Fig. 1C). Putative SNVs detected in each of the three strains
are summarized in Supplemental Table 2. Among them, 5 and 13
SNVs resulting in amino acid substitutions were found in PLK/
DUAL res.1 and res.2, respectively (Table 1). Putative SNVs were
distributed throughout the genome (Fig. 1C), however both resis-
tant clones contained mutations in gene TGME49_112570
(Table 1).
3.3. Sequence analysis of mutated TgMAPK1
The region surrounding the mutation sites of TGME49_112570
(T. gondii mitogen activated protein kinase 1: TgMAPK1) was
aligned with HsErk5 and CpCDPK1 to identify the ATP binding site.
Structural homology was also used to predict the relationship be-
tween TgMAPK1 mutations and their effect on 1NM-PP1 binding
(Fig. 2A and Supplemental Fig. 1). PLK/DUAL res.1 contained a
Leu 162 to Gln mutation which falls within the protein kinase sub-
domain III. Superposing the predicted structure of TgMAPK1 on
1NM-PP1-bound CpCDPK1 (PDB: 3NCG) showed that the mutated
Leu 162 faced the naphthyl group of 1NM-PP1 (Supplemental
Fig. 1). The Ile 171 to Asn mutation in clone PLK/DUAL res.2
mapped to the protein kinase subdomain IV, the putative ATP bind-
ing site, and the predicted target of 1NM-PP1.
3.4. Construction of parasites containing a mutated locus in TgMAPK1
To conﬁrm that the mutations in TgMAPK1 were responsible for
the resistance to 1NM-PP1, we generated replacement constructscontaining a sense mutation in order to include a ClaI restriction
site to distinguish the inserted construct from the native genomic
sequence (Fig. 2B). To determine whether the mutated TgMAPK1
sequence was selected by 1NM-PP1 treatment, plasmids pTg-
MAPK1_WT, pTgMAPK1_LQ, and pTgMAPK1_IN were nucleofected
into WT strain PLK/DUAL and cultured for 3 weeks in the presence
of 1000 nM 1NM-PP1, or for 1 week without 1NM-PP1 as a control.
Nucleofected control parasites showed no detectable ClaI digested
bands after 1 week without selection (Supplemental Fig. 2A), indi-
cating a small population possessing homologous recombination at
the TgMAPK1 genomic locus. Following selection in the presence of
1000 nM 1NM-PP1, no propagating parasites were obtained from
parasites nucleofected with pTgMAPK1_WT, though propagating
parasites were obtained from parasites nucleofected with pTg-
MAPK1_LQ, and pTgMAPK1_IN. PCR-RFLP analysis showed that
PCR products generated using genomic DNA from parasites nucle-
ofected with pTgMAPK1_LQ, and pTgMAPK1_IN were readily
cleaved by ClaI (Supplemental Fig. 2B), conﬁrming that double
homologous recombination had occurred in the TgMAPK1 genomic
locus. Sequence analysis conﬁrmed the insertion of the ClaI and
L162Qmutations in 1NM-PP1-selected parasites nucleofected with
pTgMAPK1_LQ (Supplemental Fig. 2C upper panels), and the ClaI
and I171N mutations in 1NM-PP1-selected parasites nucleofected
with pTgMAPK1_IN (Supplemental Fig. 2C middle panels).
To identify the mutation that conferred the highest gain of ﬁt-
ness in the presence of 1NM-PP1, the PLK/DUAL parent strain
was transfected with a mixture of WT and mutant constructs con-
taining the TgMAPK1 genomic sequences from PLK/DUAL, PLK/
DUAL res.1, and PLK/DUAL res.2, followed by selection with
1000 nM 1NM-PP1. Sequence chromatograms from 1NM-PP1 se-
lected parasites showed the presence of a ClaI restriction site, con-
sistent with double homologous recombination at the TgMAPK1
genomic locus. Sequence chromatograms of the L162Q mutation
Table 1
Putative missense SNPs detected only in the resistant clones
Chromosome SNP position refa altb Gene id A. A. ref A.A. alt A.A. Gene annotation in ToxoDB [pfam domain search]c
PLK/DUAL res.1 Ia 416 A C TGME49_095210 7 K T Hypothetical protein [N/D]
VIII 655444 C T TGME49_030170 1005 S N Hypothetical protein [N/D]
IX 3050049 C T TGME49_089070 28 S L P-Type cation-transporting ATPase, putative
XI 2783306 A T TGME49_112570 162 L Q CMGC kinase, MAPK family (ERK) TgMAPK-1
XII 2128556 T A TGME49_017830 608 I F Hypothetical protein [N/D]
PLK/DUAL res.2 Ib 1387776 T C TGME49_009660 124 N D Hypothetical protein [coiled_coil_region, Telomerase_RBD]
V 31569 G C TGME49_096340 35 R G Hypothetical protein [N/D]
VIIa 3386982 T C TGME49_002330 62 D G Hypothetical protein [N/D]
VIIa 3845346 T A TGME49_001640 247 E V Hypothetical protein [coiled_coil_region]
VIIb 4408633 T A TGME49_056790 550 K M Hypothetical protein [ABC_transp_aux]
VIII 5884619 T C TGME49_069330 17 L P Hypothetical protein, conserved [coiled_coil_region]
IX 2981058 A G TGME49_088970 97 L P Hypothetical protein [N/D]
X 1737926 A T TGME49_026110 424 N I Copper-transporting ATPase 1, putative
X 2927056 A G TGME49_024550 296 F S Hypothetical protein [N/D]
XI 2751672 G T TGME49_112520 237 H N tRNA delta(2)-isopentenylpyrophosphate transferase, putative
XI 2783279 A T TGME49_112570 171 I N CMGC kinase, MAPK family (ERK) TgMAPK-1
XII 1029418 C A TGME49_019220 922 V F Hypothetical protein [coiled_coil_region]
XII 5957517 A T TGME49_078640 305 V D Protein inhibitor of activated STAT protein, putative
Chromosomal positions are shown for the ME49 genome model. N/D, not detected.
a Reference bases.
b Alternative bases on the positive strand of chromosomes are shown.
c For genes annotated as hypothetical proteins in ToxoDB, pfam domain search hits are shown in parentheses.
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tained the L162Q mutation, with only a small population possess-
ing the I171N mutation (Supplemental Fig. 2C lower panels).
Selected parasites were cloned by limiting dilution, and the result-
ing clone containing the TgMAPK1 Leu 162 to Gln mutation was
designated PLK/DUAL TgMAPK1L162Q.
Genomic replacement at the loci of TgMAPK1 in chromosome XI
was conﬁrmed by PCR followed by cleavage using a restriction en-
zyme. The TgMAPK1 genomic loci from PLK/DUAL and PLK/DUAL
TgMAPK1L162Q were ampliﬁed using primers genomeLocusPri-
mer_F and genomeLocusPrimer_R (Fig. 2B and Supplemental Ta-
ble 1), resulting in a 16.6-kbp product; BamHI digestion of the
PCR products produced fragments approximately 7.8 and 8.8 kbp
in length (Fig. 2C). The PCR fragment from PLK/DUAL
TgMAPK1L162Q was cut by ClaI, resulting in 11- and 5.6-kbp frag-
ments, whereas the PCR fragment from PLK/DUAL was not cut,
resulting in a fragment 16.6 kbp in length (Fig. 2C).
PLK/DUAL TgMAPK1L162Q showed an IC50 of 300 nM for 1NM-PP1
in tachyzoite growth assays (Fig. 2D). To conﬁrm that resistancewas
conferred by expression of themutated TgMAPK1 protein, we trans-
fected a TgMAPK1 overexpression construct (Supplemental Fig. 3A)
into PLK/hxgprt-parasites. Established clones were checked for pro-
tein expression by Western blotting using an anti-FLAG antibody.
Proteins from PLK/TgMAPK1-FLAG and PLK/TgMAPK1L162Q-FLAG
showed TgMAPK1-FLAG bands at 150 kDa (Supplemental
Fig. 3B). Bands were slightly higher than the calculated molecular
weight of 3xFLAG tagged TgMAPK1 (140 kDa). Protein from the
PLK/GFP-FLAG control showed a GFP-FLAG band at approximately
31 kDa. Western blotting with anti-TgALD1 antibody (Sugi et al.,
2010) was used to conﬁrm equivalent loading.
PLK/TgMAPK1-FLAG, PLK/TgMAPK1L162Q-FLAG, and PLK/GFP-
FLAG were examined by plaque assay with or without 1NM-PP1.
PLK/GFP-FLAG showed no plaque at 250 nM 1NM-PP1 (Supple-
mental Fig. 3C). PLK/TgMAPK1-FLAG showed a small plaque at
250 nM 1NM-PP1 (Supplemental Fig. 3C), while PLK/
TgMAPK1L162Q-FLAG showed a medium sized plaque at 250 nM
1NM-PP1 (Supplemental Fig. 3C). These results suggest that over-
expression of TgMAPK1 is sufﬁcient to confer modest resistance
to 1NM-PP1, while overexpression of TgMAPK1 L162Q confers
higher resistance to 1NM-PP1 than WT TgMAPK1 or control GFP
expression alone.3.5. Inhibitory effect of 1NM-PP1 on invasion, egress, and cell division
of TgMAPK1 mutant L162Q
Previous reports have demonstrated an inhibitory effect of BKIs
on invasion and calcium-induced egress through targeting of
TgCDPK1; we therefore examined whether these mechanisms
might also be contributing to 1NM-PP1 inhibition of TgMAPK1.
500 nM 1NM-PP1 reduced invasion of PLK/DUAL parasites by
>40% relative to untreated controls (Fig. 3A). PLK/DUAL res.1,
PLK/DUAL res.2, and PLK/DUAL TgMAPK1L162Q showed similar lev-
els of 1NM-PP1 susceptibility in terms of invasion inhibition, with
no signiﬁcant differences observed.
Calcium-induced egress was also examined. Parasites were trea-
tedwithA23187, a calcium ionophore that causes increasedCa2+ con-
centration in parasites leading to egress of parasites from infected
cells, with orwithout 1NM-PP1. All constructs (PLK/DUAL, PLK/DUAL
res.1, PLK/DUAL res.2, and PLK/DUAL TgMAPK1L162Q) showed a simi-
lar decrease in A23187-induced egress. Egress rates were approxi-
mately 80% for all constructs in the absence of drug; this rate
dropped to <20% upon addition of 250 nM 1NM-PP1 (Fig. 3B).
As a ﬁnal step we examined tachyzoite cell division. At 12 h, the
average numbers of parasites per vacuole of PLK/DUAL, PLK/DUAL
res.1, PLK/DUAL res.2, and PLK/DUAL TgMAPK1L162Q were 1.58, 1.61,
1.60, and 1.60 without 1NM-PP1 treatment and 1.31, 1.53, 1.43, and
1.54 with 250 nM 1NM-PP1 treatment, respectively (Fig. 4A). At
24 h the average numbers of parasites per vacuole of PLK/DUAL,
PLK/DUAL res.1, PLK/DUAL res.2, and PLK/DUAL TgMAPK1L162Q were
4.85, 4.83, 4.62 and 4.81 without 1NM-PP1 treatment and 3.53,
4.38, 4.33, and 4.56 with 250 nM 1NM-PP1 treatment, respectively
(Fig. 4A). These results demonstrate a signiﬁcant change in parasite
numbers between the WT PLK/DUAL strain and resistant clones in
the presence of 250 nM 1NM-PP1 at both 12 and 24 h (Fig. 4A), sug-
gesting that TgMAPK1mutational resistance to 1NM-PP1 is mediated
through cell division regulation in drug susceptibility.
3.6. Effect of TgMAPK1 mutations on susceptibility to other BKIs
TgMAPK1 mutants L162Q and I171N were next examined for
cross resistance to other BKIs. 3BrB-PP1 inhibited clones PLK/
DUAL, PLK/DUAL res.1, PLK/DUAL res.2, and PLK/DUAL
TgMAPK1L162Q at IC50 values of 41, 81, 30 and 95 nM, respectively
Fig. 2. 1NM-PP1 selects for mutations in TgMAPK1. (A) Alignment of the mutated region of TgMAPK1 with proteins HsErk5 and CpCDPK1. ‘⁄’ indicates the ATP-binding amino
acid position, ‘+’ indicates the 1NM-PP1 bound amino acid position in CpCDPK1, and ‘#’ indicates the position of the gatekeeper residue. (B) Schematic depicting the
chromosomal DNA around TGME49_112570 and a replacement construct. The blue boxes show coding sequences for genes TGME49_112560 and TGME49_112580. The red
box shows the TGME49_112570 exon on the negative strand of chromosome XI. Arrows represent primers genomeLocusPrimer_F and genomeLocusPrimer_R used in PCR-
RFLP analysis. A ClaI restriction site is contained in all plasmids; mutations L162Q and I171N are encoded by plasmids pTgMAPK1_LQ and pTgMAPK1_IN, respectively. (C) PCR
fragments of chromosome XI 2,772,456–2,789,052 from PLK/DUAL and PLK/DUAL TgMAPK1L162Q were cut with ClaI or BamHI and separated by 0.7% agarose gel
electrophoresis. (D) Tachyzoite growth inhibition by 1NM-PP1 was determined by measuring DsRed Express ﬂuorescent reporter expression. Cells were cultured for 6 days;
ﬂuorescent signals in cell lysates were detected using a ﬂuorimeter, and expressed as relative ﬂuorescent units. Error bars indicate the standard deviations across three
independent experiments. IC50 values are inset.
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tern of sensitivity, with IC50 values for PLK/DUAL, PLK/DUAL
res.1, PLK/DUAL res.2, and PLK/DUAL TgMAPK1L162Q of 73, 146,
90 and 176 nM, respectively (Supplemental Fig. 4B). Parasite
clones harboring the L162Q mutation showed consistently higher
IC50 values for both 3BrB-PP1 and 3MB-PP1 compared to the
parental strain PLK/DUAL. On the other hand, parasite clones
expressing the I171N mutation (PLK/DUAL res.2) showed similar
IC50 value to 3BrB-PP1 and 3MB-PP1 as PLK/DUAL, demonstrating
selective resistance to BKI 1NM-PP1.4. Discussion
In T. gondii, the main target of 1NM-PP1 is TgCDPK1 (Lourido
et al., 2010; Ojo et al., 2010; Sugi et al., 2010; Larson et al.,2012). This report represents the ﬁrst description of mutations in
TgMAPK1 capable of conferring resistance to 1NM-PP1. Mutants
were generated using random mutagenesis followed by whole-
genome sequencing. Considering the hundreds of SNVs detected
by whole-genome sequencing, a lower concentration of ENU may
be sufﬁcient for whole genome mutagenesis. By decreasing the
number of SNVs in a given sequence, identiﬁcation of the mutation
responsible for a desired phenotype becomes much easier. Surpris-
ingly neither resistant clone had mutations in TgCDPK1. As this
study failed to identify the known target of 1NM-PP1, higher con-
centration of ENU or larger starting parasites number may be use-
ful for developing more robust target identiﬁcation.
The method we chose for generating resistant clones in this
study was somewhat slower than the usual selection time of 3 days
to 1 week using the standard selectable marker HXGPRT to isolate
transgenic parasites. Instead we selected for 3 weeks (three
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Fig. 3. Parental PLK/DUAL and resistant clones had comparable susceptibility to 1NM-PP1 at invasion and calcium-induced egress. (A) Parasites were allowed to invade for 30
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Fig. 4. Tachyzoite cell division rates of resistant clones were not decreased in the presence of 1NM-PP1. (A) Average parasite number per vacuole after 12 and 24 h incubation,
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ing, parasites were cloned and propagated in the absence of selec-
tion pressure, meaning the time necessary to establish clones after the
screening was almost the same as with standard transgenic parasites.
The resistant clones did not demonstrate resistance to 1NM-PP1
at invasion or egress where TgCDPK1 has been shown to play an
important role (Lourido et al., 2010). Instead, resistance was
mediated through altered susceptibility during cell division. Thisalternative pattern of resistance may not be achieved through
complementation of TgCDPK1 function directly, but instead by res-
cuing a different inhibitory effect of 1NM-PP1 on cell division
which had not previously been evaluated. Considering that
TgMAPK1 has been shown to function in stress responses (Brmlik
et al., 2011), inhibition of TgMAPK1 could affect the parasite’s abil-
ity to respond to different stresses caused by 1NM-PP1, including
TgCDPK1 inhibition.
100 T. Sugi et al. / International Journal for Parasitology: Drugs and Drug Resistance 3 (2013) 93–101The PLK/DUAL reporter strain is an excellent system for measur-
ing bradyzoite differentiation using a ﬂuorescent reporter (Unno
et al., 2009). Our resistant clones and BKIs may represent a valu-
able tool to study the function of TgMAPK1 in bradyzoite
differentiation.
The tachyzoite cell cycle is regulated by several protein kinase
signals, including a PKA signal inhibited by a cAMP analog (Eaton
et al., 2006), PKA speciﬁc inhibitors (Kurokawa et al., 2011),
TgNEK1 (Gubbels et al., 2008), TPK2 (Khan et al., 2002), and a
MAPK signal inhibited by p38 MAPK inhibitors (Wei et al., 2002).
Analysis of the T. gondii genome suggests that the MAPK signaling
cascade lacks the canonical upstream protein kinase STE group
(Miranda-Saavedra et al., 2012). While its role in the cell cycle is
not yet clear, TgMAPK1 may interact with the protein kinase sig-
nals described above instead of STE.
Among the putative SNVs detected, both resistant clones had a
mutation in TgMAPK1. PLK/DUAL res.2 carried a mutation at the
predicted ATP and 1NM-PP1 binding site (Ile171). Protein kinase
activity may be altered by this mutation; however, no signiﬁcant
change in tachyzoite growth was observed in the absence of
1NM-PP1. Furthermore, the mutated site in PLK/DUAL res.1
(Leu162) was predicted to face the nonpolar naphthyl group of
1NM-PP1 (Supplemental Fig. 1). The polar characteristics of Gln
162 in these resistant parasites might disrupt the nonpolar interac-
tion, decreasing the afﬁnity between 1NM-PP1 and TgMAPK1.
Generation of the active recombinant enzyme will be necessary
for in vitro kinase assays. In vitro assays will allow for detailed anal-
yses of protein kinase activity in the presence of inhibitors such as
1NM-PP1, as well as the effect of mutations on enzyme activity.
Preliminary efforts to isolate the active form of TgMAPK1 were
unsuccessful. A truncated isoform of TgMAPK1 containing the en-
tire protein kinase domain (GenBank ID: AY684849) fused with
the maltose binding protein or glutathione S transferase was ex-
pressed in Escherichia coli or using a baculovirus system; however,
the resulting protein did not exhibit sufﬁcient enzymatic activity
for use in drug inhibition assays (data not shown). One possible
explanation for this deﬁciency may be tied to enzyme regulation.
MAPKs from other species require activation by corresponding
MAPKKs for full enzyme activity. Identiﬁcation of protein kinases
which can activate TgMAPK1 may therefore be necessary.
The full length isoform of TgMAPK1, which is predicted by both
RNA-seq and gene modeling data in ToxoDB, alters the susceptibil-
ity of parasites to 1NM-PP1 when expressed in parasites, suggest-
ing that this isoform may contribute to kinase activity. Attempts at
expressing the full-length TgMAPK1 isoform in E. coli were also
unsuccessful; an alternative system suitable for the expression of
large proteins will therefore be needed.
Parasite clones expressing an L162Q mutation in TgMAPK1
exhibited cross resistance to other BKIs (3BrB-PP1 and 3MB-PP1),
suggesting a more universal role for TgMAPK1 in BKI resistance.
The possibility of mutations beyond TgCDPK1 should therefore
be considered when BKI resistance is observed. Alternatively,
clones possessing the I171N mutation in TgMAPK1 (PLK/DUAL
res.2) showed similar susceptibilities to 3MB-PP1, along with
slightly higher susceptibilities to 3BrB-PP1. The speciﬁcity of this
mutation to 1NM-PP1 suggests structural differences between
this and other BKIs, which may provide insight into the activity
of this compound.
BKI derivatives with enhanced activity against TgCDPK1 have
been reported recently (Larson et al., 2012). This activity is medi-
ated through substitutions at the R2 position of the PP-based
inhibitor. TgMAPK1 mutations described here aligned to the naph-
thyl group at the R1 position (Supplemental Fig. 1). Resistant
clones in the present report may not be cross resistant to R2 substi-
tuted derivatives; however, use of resistant parasite clones is
necessary to predict the occurrence of BKI resistance in T. gondii.The mutation in TgMAPK1 conferring resistance to 1NM-PP1
did not occur at the gatekeeper residue, suggesting the likelihood
of similar mutations that may confer resistance in other analog
sensitive kinases. Genome-wide screening these and other non-
gatekeeper mutation conferring resistance to BKIs is therefore
warranted. This work demonstrates the usefulness of random
mutagenesis followed by whole-genome sequencing for the
screening of such mutations.
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